CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.94−0.05 (-2.27%)
Close on Nov 17, 2026Market cap $422.73MP/E –Yield –
CytomX Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CytomX Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$87.15M, down 302.1% year over year. For fiscal 2025 it was -$22.36M, down 189.5% from the year before. The highest annual figure on record is $25.00M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.36M | -189.5% |
| FY2024 | Dec 31, 2024 | $25.00M | – |
| FY2023 | Dec 31, 2023 | -$6.48M | – |
| FY2022 | Dec 31, 2022 | -$101.34M | – |
| FY2021 | Dec 31, 2021 | -$116.04M | – |
| FY2020 | Dec 31, 2020 | -$80.54M | – |
| FY2019 | Dec 31, 2019 | -$141.48M | – |
| FY2018 | Dec 31, 2018 | -$77.87M | – |
| FY2017 | Dec 31, 2017 | -$46.26M | – |
| FY2016 | Dec 31, 2016 | -$59.59M | – |
| FY2015 | Dec 31, 2015 | -$33.20M | – |
| FY2014 | Dec 31, 2014 | -$29.77M | – |
| FY2013 | Dec 31, 2013 | -$14.96M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$23.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.67M | -187.0% |
| Q4 FY2025 | Dec 31, 2025 | -$27.93M | -258.0% |
| Q3 FY2025 | Sep 30, 2025 | -$15.77M | -483.6% |
| Q2 FY2025 | Jun 30, 2025 | -$1.29M | – |
| Q1 FY2025 | Mar 31, 2025 | $22.62M | +94.1% |
| Q4 FY2024 | Dec 31, 2024 | $17.68M | – |
| Q3 FY2024 | Sep 30, 2024 | $4.11M | +31.6% |
| Q2 FY2024 | Jun 30, 2024 | -$8.45M | – |
| Q1 FY2024 | Mar 31, 2024 | $11.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$606.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $3.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.65M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.51M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.05M | – |
| Q1 FY2022 | Mar 31, 2022 | -$32.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$34.90M | – |
| Q3 FY2021 | Sep 30, 2021 | -$31.04M | – |
| Q2 FY2021 | Jun 30, 2021 | -$26.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$24.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$25.22M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.76M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.49M | – |
| Q4 FY2019 | Dec 31, 2019 | -$67.97M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.72M | – |
| Q2 FY2019 | Jun 30, 2019 | -$31.23M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.57M | – |
| Q4 FY2018 | Dec 31, 2018 | -$25.81M | – |
| Q3 FY2018 | Sep 30, 2018 | -$23.18M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.26M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.63M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.25M | – |
| Q3 FY2017 | Sep 30, 2017 | -$11.03M | – |
| Q2 FY2017 | Jun 30, 2017 | -$25.37M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.61M | – |
| Q4 FY2016 | Dec 31, 2016 | -$14.23M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.92M | – |
See a number that looks wrong?